A new therapeutic lead in the treatment of glioblastoma

Published on

The Marseille Cancer Research Center celebrates its 50th anniversary ! -

Pasquier team published in EBioMedicine (The Lancet)


Nine targetable vulnerabilities were identified in glioblastoma and the top gene hit RRM1 was validated as an independent prognostic factor. The associations of CHK1/MEK and AURKA/BET inhibitors were identified as the most potent amongst 528 tested pairwise drug combinations and their efficacy was validated in 3D spheroid models. The high synergism of AURKA/BET dual inhibition was confirmed in ex vivo and in vivo glioblastoma models, without detectable toxicity.


To know more

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms
Ariey-Bonnet J, Berges R, Montero MP, Mouysset B, Piris P, Muller K, Pinna G, Failes TW, Arndt GM, Morando P, Baeza-Kallee N, Colin C, Chinot O, Braguer D, Morelli X, André N, Carré M, Tabouret E, Figarella-Branger D, Le Grand M, Pasquier E.
EBioMedicine. 2023 Aug 10;95:104752. doi: 10.1016/j.ebiom.2023.104752. Epub ahead of print. PMID: 37572644; PMCID: PMC10433015.